Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Of The Week’s Takeaway From PSA: Optimism With Aches

Executive Summary

The federal government is on the verge of a shutdown and the Affordable Care Act is creating jitters across every corner of the health care system, but the tone at last week’s 23rd annual Pharmaceutical Strategy Conference was surprisingly optimistic, even regarding vulnerabilities at the core of biopharma’s well-being: the quality of its R&D, FDA predictability and its commercial model.

You may also be interested in...



Asia Spotlight: In China, Multinationals Tap Closer R&D Ties With Domestics

As the Chinese government becomes more assertive in regulatory and enforcement activity, Big Pharma like Eli Lilly are turning to partnerships with local companies to foster closer ties with stakeholders, get policy support and accelerate R&D via green channels.

Bonding Time In China: Multinationals Tap Closer R&D Ties With Domestics

As the Chinese government becomes more assertive in regulatory and enforcement activity, Big Pharma like Eli Lilly are turning to partnerships with local companies to foster closer ties with stakeholders, get policy support and accelerate R&D via green channels.

Finding The Value In Shifting R&D Models

Consultancy McKinsey & Co. is optimistic about the future of R&D within the pharma industry, but says certain aspects of the organizations need to shift – making the companies leaner and more productive – to maintain the industry’s leadership position.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel